Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2 Induction Courses of BCG for High Risk Superficial Bladder Cancer
NCT02281383Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2014
- Primary completion
- Feb 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of bcg vaccine in bladder cancer, sponsored by Memorial Sloan Kettering Cancer Center. Started Oct 2014; status: completed.
02
Drugs
bcg vaccine
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT02281383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02281383.